JP2022533368A5 - - Google Patents
Info
- Publication number
- JP2022533368A5 JP2022533368A5 JP2021568537A JP2021568537A JP2022533368A5 JP 2022533368 A5 JP2022533368 A5 JP 2022533368A5 JP 2021568537 A JP2021568537 A JP 2021568537A JP 2021568537 A JP2021568537 A JP 2021568537A JP 2022533368 A5 JP2022533368 A5 JP 2022533368A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- compound
- composition according
- administered
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962849185P | 2019-05-17 | 2019-05-17 | |
| US62/849,185 | 2019-05-17 | ||
| PCT/US2020/033232 WO2020236636A1 (en) | 2019-05-17 | 2020-05-15 | Methods of treating a mk2-mediated disorder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022533368A JP2022533368A (ja) | 2022-07-22 |
| JP2022533368A5 true JP2022533368A5 (enExample) | 2023-05-18 |
Family
ID=73459478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021568537A Pending JP2022533368A (ja) | 2019-05-17 | 2020-05-15 | Ｍｋ２媒介性障害の治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220251105A1 (enExample) |
| EP (1) | EP3969456A4 (enExample) |
| JP (1) | JP2022533368A (enExample) |
| KR (1) | KR20220041042A (enExample) |
| CN (1) | CN114364681A (enExample) |
| WO (1) | WO2020236636A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62017B1 (sr) | 2014-09-17 | 2021-07-30 | Celgene Car Llc | Mk2 inhibitori i njihova upotreba |
| EP3596086A4 (en) | 2017-03-16 | 2020-12-16 | Celgene CAR LLC | MK2 INHIBITORS, THEIR SYNTHESIS AND THEIR INTERMEDIARIES |
| US11124525B2 (en) | 2017-03-16 | 2021-09-21 | Celgene Car Llc | Heteroaryl compounds useful as MK2 inhibitors |
| AU2018236286B2 (en) | 2017-03-16 | 2022-02-17 | Bristol-Myers Squibb Company | Forms and compositions of a MK2 inhibitor |
| WO2022020562A1 (en) * | 2020-07-24 | 2022-01-27 | Bristol-Myers Squibb Company | Methods of treating acute respiratory disorders |
| EP4284805A1 (en) | 2021-02-01 | 2023-12-06 | Celgene Corporation | Mk2 inhibitors, the synthesis thereof, and intermediates thereto |
| EP4464694A4 (en) | 2022-01-14 | 2026-04-01 | Shanghai Hansoh Biomedical Co Ltd | POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE |
| CN116643046B (zh) * | 2023-05-30 | 2025-09-12 | 南昌市高新区人民医院(南昌大学第一附属医院高新医院) | Mk2在癌症恶病质肌肉萎缩中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040131614A1 (en) * | 2002-07-19 | 2004-07-08 | Abbott Biotechnology Ltd. | Treatment of pulmonary disorders using TNFalpha inhibitor |
| GB0520164D0 (en) * | 2005-10-04 | 2005-11-09 | Novartis Ag | Organic compounds |
| JP2014088342A (ja) * | 2012-10-30 | 2014-05-15 | Kowa Company Ltd | ベンゾオキサジアゾール誘導体を有効成分とするｍｋ２阻害剤 |
| US9545407B2 (en) * | 2014-08-07 | 2017-01-17 | Pharmacyclics Llc | Formulations of a bruton's tyrosine kinase inhibitor |
| CN107427524A (zh) * | 2014-08-28 | 2017-12-01 | 翁科埃斯克斯有限公司 | 利用包含噻吩并三唑并二氮杂*化合物的药物组合物治疗急性髓细胞白血病或急性淋巴性白血病的方法 |
| RS62017B1 (sr) * | 2014-09-17 | 2021-07-30 | Celgene Car Llc | Mk2 inhibitori i njihova upotreba |
| EP3596086A4 (en) * | 2017-03-16 | 2020-12-16 | Celgene CAR LLC | MK2 INHIBITORS, THEIR SYNTHESIS AND THEIR INTERMEDIARIES |
| EP3596084A4 (en) * | 2017-03-16 | 2020-12-23 | Celgene CAR LLC | 9,10,11,12-TETRAHYDRO-8H- [1,4] DIAZEPINO [5 ', 6': 4,5] THIÉNO [3,2-F] QUINOLIN-8-ONE COMPOUNDS AND THEIR USES |
| US11124525B2 (en) * | 2017-03-16 | 2021-09-21 | Celgene Car Llc | Heteroaryl compounds useful as MK2 inhibitors |
| AU2018236286B2 (en) * | 2017-03-16 | 2022-02-17 | Bristol-Myers Squibb Company | Forms and compositions of a MK2 inhibitor |
-
2020
- 2020-05-15 WO PCT/US2020/033232 patent/WO2020236636A1/en not_active Ceased
- 2020-05-15 CN CN202080044746.6A patent/CN114364681A/zh active Pending
- 2020-05-15 US US17/611,594 patent/US20220251105A1/en not_active Abandoned
- 2020-05-15 KR KR1020217041270A patent/KR20220041042A/ko not_active Ceased
- 2020-05-15 EP EP20810459.6A patent/EP3969456A4/en not_active Withdrawn
- 2020-05-15 JP JP2021568537A patent/JP2022533368A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1755561B1 (en) | Multi-layer tablet comprising non-steroidal anti-inflammatory drugs decongestants and non-sedating antihistamines | |
| JP2023002662A5 (enExample) | ||
| JP2025186241A5 (enExample) | ||
| JP2021519288A5 (enExample) | ||
| JP2005515966A5 (enExample) | ||
| CN107260695A (zh) | 硝唑尼特的控制释放药物剂型 | |
| JP2018504398A5 (enExample) | ||
| JP2004531549A5 (enExample) | ||
| JP2026035701A5 (enExample) | ||
| JP2021504384A5 (enExample) | ||
| JP2022535893A5 (enExample) | ||
| CN105338970B (zh) | 包含他达拉非和坦洛新的药物胶囊复合制剂 | |
| JP2024502446A5 (enExample) | ||
| JPS6241646B2 (enExample) | ||
| JP2005528429A (ja) | 活性成分の徐放性を有するオクスカルバゼピン含有薬学的組成物 | |
| JP2022500485A5 (enExample) | ||
| JP2022535894A5 (enExample) | ||
| JP2022540348A5 (enExample) | ||
| JP2019507786A5 (enExample) | ||
| JP2023510965A5 (enExample) | ||
| JP2022177119A5 (enExample) | ||
| CZ132698A3 (cs) | Farmaceutický přípravek pro ošetřování poruch autoimunity | |
| JP2008533022A5 (enExample) | ||
| JP2024545496A5 (enExample) | ||
| CN1863512A (zh) | 控释药物组合物及其制备方法 |